Study of AMV564 in Subjects With Advanced Solid Tumors

Amphivena Therapeutics

Status and phase

Unknown

Phase 1

Conditions

Locally Advanced or Metastatic Solid Tumors

Treatments

Biological: AMV564

Study type

Interventional

Funder types

Industry

Identifiers

NCT04128423

AMV564-301

Details and patient eligibility

About

This Phase 1 study is designed to assess the safety, tolerability, pharmacokinetics, and preliminary efficacy of AMV564 alone and in combination with Pembrolizumab in patients with advanced solid tumors.

Full description

AMV564-301 is a Phase 1, open-label, multicenter dose-escalation with expansion trial in patients with locally advanced or metastatic solid tumors. In the dose-escalation portion of the study, cohorts of patients will receive AMV564 alone or in combination with Pembrolizumab at increasing dose levels to determine the maximum tolerated dose (MTD) and/or the recommended dose for expansion. In the expansion portion of the study, one or more cohorts of patients will receive AMV564 at the MTD or recommended dose to further evaluate safety, tolerability, and clinical activity.

Enrollment

65 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion and exclusion criteria

Key Inclusion Criteria:

18 years of age or older
Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2
Histologically or cytologically documented, incurable or metastatic solid tumor that is advanced (non-resectable) or recurrent and progressing since the last anti-tumor therapy and for which no recognized standard therapy exists
Measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 or per other criteria best suited for the specific tumor type being evaluated
Willing to complete all scheduled visits and assessments at the institution administering therapy

Key Exclusion Criteria:

Treatment with any local or systemic antineoplastic therapy (including chemotherapy, hormonal therapy, or radiation) within 3 weeks prior to first dose of AMV564
Major trauma or major surgery within 4 weeks prior to first dose of AMV564
Prior treatment with chimeric antigen receptor (CAR) T-cell therapy or T-cell engager therapy
Chronic use of corticosteroids in excess of 10 mg daily of prednisone or equivalent within 4 weeks prior to first dose of AMV564
Adverse events from prior anti-cancer therapy that have not resolved to Grade ≤ 1 except for alopecia
Known, central nervous system (CNS) disease involvement, or prior history of National Cancer Institute Common Toxicity Criteria for Adverse Events (NCI CTCAE) Grade ≥ 3 drug-related CNS toxicity